Who are we?

Founded in May 2021, we are committed to becoming an internationally competitive platform for the discovery and application of innovative peptides molecules, with independent high-throughput biological screening of peptide entity diversity libraries as the core technology base. We have set up a high-level technical team for innovation and development led by national and provincial distinguished experts with senior industry experience, and several senior academicians in the field of peptides in China and Switzerland have served as technical consultants to provide important support for the development and internationalization of innovative peptide drugs.

We have been selected as a key contract introduction project of the "5050 Plan" for overseas high-level talents' innovation and entrepreneurship in Hangzhou High-tech Zone (Binjiang) and obtained the angel round strategic investment of tens of millions of RMB of thunderstorm capital.